Clinical Trials of Immunotherapy of Cancer Utilizing Cytotoxic Cells

  • Stephen E. Ettinghausen
  • Steven A. Rosenberg


Standard therapies for patients with cancer have traditionally included surgery, chemotherapy, and radiation. Since the 1960s, however, there has been increasing interest in the use of a biologic or immunologic therapy to treat cancer in man (Rosenberg et al., 1989a; Rosenberg, 1991). Within the realm of biologic therapy, the greatest therapeutic promise lies with manipulations of the cellular arm of the immune system, since cellular host mechanisms are responsible for elimination of transplanted tissues bearing foreign proteins (Rosenberg and Terry, 1977).


Renal Cell Carcinoma Human Leukocyte Antigen Autologous Tumor Activate Killer Cell Adoptive Immunotherapy 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aebersold P, Carter CS, Hyatt C, et al. (1988): A simplified automated procedure for generation of human lymphokine-activated killer cells for use in clinical trials. J Immunol Methods 112: 1–7Google Scholar
  2. Aebersold P, Hyatt C, Johnson S, et al. (1991): Lysis of autologous melanoma cells by tumor, infiltrating lymphocytes: Association with clinical response. J Nat(Cancer Inst 83: 932–937Google Scholar
  3. Alexander RB, Rosenberg SA (1990): Long term survival of adoptively-transferred tumor infiltrating lymphocytes in mice. J Immunol 145: 1615–1620Google Scholar
  4. Alexander RB, Rosenberg SA (1991): Adoptively transferred tumor-infiltrating lymphocytes can cure established metastatic tumor in mice and persist long-term in vivo as functional memory T lymphocytes. J Immunother 10: 389–397Google Scholar
  5. Anderson WF (1992): Human gene therapy. Science 256: 808–813Google Scholar
  6. Andriole GL, Mulé JJ, Hansen CT, et al. (1985): Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J Immunol 135: 2911–2913Google Scholar
  7. Asher AL, Mulé JJ, Kasid A, et al. (1991): Murine tumor cells transduced with the gene for tumor necrosis factor-y: Evidence for paracrine immune effects of tumor necrosis effect against tumor. J Immunol 146: 3227–3234Google Scholar
  8. Asher AL, Mulé JJ, Reichert CM, et al. (1987): Studies of the anti-tumor efficacy of systematically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963–974Google Scholar
  9. Atkins MB, Mier JW, Parkinson DR, et al. (1988): Hypo-thyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 318: 15571563Google Scholar
  10. Balch CM, Riley LB, Bae TJ, et al. (1990): Patterns of human tumor infiltrating lymphocytes in 120 human cancers. Arch Surg 125: 200–205Google Scholar
  11. Bar M, Sznol M, Atkins MB, et al. (1990): Metastatic melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine activated killer cells. J Clin Oncol 8: 1138–1147Google Scholar
  12. Barba D, Saris SC, Holder C, et al. (1988): Immunotherapy of human glial tumors: Report of multiple dose intratumoral infusions of lymphokine-activated killer cells and interleukin-2. J Neurosurg 70: 175–182Google Scholar
  13. Barth RJ, Jr, Bock SN, Mulé JJ, et al. (1990): Unique murine tumor associated antigens identified by tumor infiltrating lymphocytes. J Immunol 144: 1531–1537Google Scholar
  14. Barth RJ, Mulé JJ, Asher AL, et al. (1991a): Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor. J Immunol Methods 140: 269–279Google Scholar
  15. Barth RJ, Jr, Mulé JJ, Spiess PJ, et al. (1991b): Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor infiltrating lymphocytes. J Exp Med 173: 647–658Google Scholar
  16. Belldegrun A, Muul LM, Rosenberg SA (1988): Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and anti-tumor activity. Cancer Res 48: 206–214Google Scholar
  17. Belldegrun A, Webb DE, Austin HA, et al. (1987): Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer. Ann Intern Med 106: 817–822Google Scholar
  18. Belldegrun A, Webb DE, Austin HA, et al. (1989): Renal toxicity of interleukin-2 administration in patients with metastatic renal cell cancers: Effect of pretherapy nephrectomy. J Urol 141: 499–503Google Scholar
  19. Blankenstein T, Quin Z, Uberla K, et al. (1991): Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med 173: 1047–1052Google Scholar
  20. Bock SN, Lee RE, Fisher B, et al. (1990): A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J Clin Oncol 8: 161–169Google Scholar
  21. Cameron RB, Spiess PJ, Rosenberg SA (1990): Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin-2 and local tumor irradiation: Studies on the mechanism of action. J Exp Med 171: 249–263Google Scholar
  22. Colombo MP, Gerrari G, Stoppacciaro A, et al. (1991): Granulo-cyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 173: 889–897Google Scholar
  23. Cotran RS, Pober JS, Gimbrone MS, Jr, et al. (1988): Endothelial activation during interleukin-2 (IL-2) immunotherapy: A possible mechanism for the vascular leak syndrome. J Immunol 140: 1883–1888Google Scholar
  24. Culver KW, Anderson WF, Blaese RM (1991a): Lym- phocyte gene therapy. Hum Gene Ther 2: 107–109Google Scholar
  25. Culver K, Cornetta K, Morgan R, et al. (1991b): Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proc Nall Acad Sci USA 88: 3155–3159Google Scholar
  26. Darrow TL, Slingluff CL, Seigler HF (1989): The role of class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: Evidence for shared tumor antigens. J Immunol 142: 3329–3335Google Scholar
  27. Denicoff KD, Durkin TM, Lotze MT, et al. (1989): The neuroendocrine effects of interleukin-2 treatment. J Clin Endocrinol Metab 69: 402–410Google Scholar
  28. Denicoff KD, Rubinow DR, Papa MZ, et al. (1987): The neuropsychiatric effects of the treatment with interleukin-2 and lymphokine activated killer cells. Ann Intern Med 107: 293–300Google Scholar
  29. Dutcher JP, Creekmore S, Weiss GR, et al. (1989): A phase II study of interleukin-2 and lymphokine activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7: 477–485Google Scholar
  30. Dutcher JP, Gaynor ER, Boldt DH, et al. (1991): A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J Clin Oncol 9: 641–648Google Scholar
  31. Eglitis MA, Anderson WF (1988): Retroviral vectors for introduction of genes into mammalian cells. Bio Techniques 6: 608–614Google Scholar
  32. Eisenthal A, Cameron RB, Uppenkamp I, et al. (1988a): Effect of combined therapy with lymphokine-activated killer cells, interleukin-2 and specific monoclonal antibody on established B16 melanoma lung metastases. CancerRes 48: 7140–7145Google Scholar
  33. Eisenthal A, Shiloni E, Rosenberg SA (1988b): Characterization of IL-2 induced murine cells which exhibit ADCC activity. Cell Immunol 115: 257–272Google Scholar
  34. Ettinghausen SE, Lipford EH, Mulé JJ, et al. (1985): Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine activated killer (LAK) cells. J Immunol 135: 3623–3635Google Scholar
  35. Ettinghausen SE, Moore JG, White DE, et al. (1987): Hematologic effects of immunotherapy with lymphokine activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69: 1654–1660Google Scholar
  36. Ettinghausen SE, Puri RK, Rosenberg SA (1988): Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Nall Cancer Inst 80: 177–188Google Scholar
  37. Fearon ER, Pardoll DM, Itaya T, et al. (1990): Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397–403Google Scholar
  38. Fisher B, Packard BS, Read EJ, et al. (1989): Tumor localization of adoptively transferred indium-I11 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7: 250–61Google Scholar
  39. Fisher RI, Coltman CA, Doroshow JH, et al. (1988): Metastatic renal cancer treated with interleukin-2 and lymphokine activated killer cells. A phase II clinical trial. Ann Int Med 108: 518–523Google Scholar
  40. Fox B, Rosenberg SA (1989): Heterogeneous lymphokine-activated killer cell precursor populations. Cancer Immunol Immunother 29: 115Google Scholar
  41. Fujita T, Takaoka C, Matsui H, et al. (1983): Structure of the human interleukin-2 gene. Proc Nat! Acad Sci USA 80: 7437–7441Google Scholar
  42. Galili U, Vanky F, Rodriquez L, et al. (1979): Activated T lymphocytes within human solid tumors. Cancer Immunol Immunother 6: 129–133Google Scholar
  43. Gansbacher B, Bannerji R, Daniels B, et al. (1990a): Retroviral vector-mediated y-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res 50: 7820–7825Google Scholar
  44. Gansbacher B, Zier K, Daniels B, et al. (19906): Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217–1224Google Scholar
  45. Gaspari AA, Lotze MT, Rosenberg SA, et al. (1987): Dermatologie changes associated with interleukin-2 administration. JAMA 258: 1624–1629Google Scholar
  46. Gaynor ER, Weiss GR, Margolin KA, et al. (1990): Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinoma. J Natl Cancer Inst 82: 1397–1402Google Scholar
  47. Giboa E, Eglitis MA, Kantoff PW, et al. (1986): Transfer and expression of cloned genes using retroviral vectors. Bio Techniques 4: 504–512Google Scholar
  48. Golumbek PT, Lazenby AJ, Levitsky HI, et al. (1991): Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713716Google Scholar
  49. Griffith KD, Read EJ, Carrasquillo CS, et al. (1989): In vivo distribution of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 81: 1709–1717Google Scholar
  50. Grimm EA, Rosenberg SA (1984): The human lymphokine-activated killer cell phenomenon. In: Lymphokines, Pick E, Candy M, eds. New York: Academic Press, Vol 9, p. 279Google Scholar
  51. Grimm EA, Mazumder A, Zhang HZ, et al. (1982): Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841Google Scholar
  52. Grimm EA, Ramsey KM, Mazumder A, et al. (1983a): Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157: 884–897Google Scholar
  53. Grimm EA, Robb RJ, Roth JA, et al. (19836): Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158: 1356–1361Google Scholar
  54. Gross G, Waks T, Eshhar Z (1989): Expression of immunoglobulin-T cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86: 10023–10028Google Scholar
  55. Haas GP, Solomon D, Rosenberg SA (1990): Tumor infiltrating lymphocytes from non renal urological malignancies. Cancer Immunol Immunother 30: 342–350Google Scholar
  56. Hawkins MT (1989): PPO updates IL-2/LAK. Princ Pract Oncol 3: 1–14Google Scholar
  57. Heo DL, Whiteside TL, Johnson JT, et al. (1987): Longterm interleukin-2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 47: 6353–6362Google Scholar
  58. Heo DS, Whiteside TL, Kanbour A, et al. (1988): Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2 activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol 140: 4042–4049Google Scholar
  59. Horn SS, Topalian SL, Simoni ST, et al. (1991): Common expression of melanoma tumor-associated antigens recognized by human tumor-infiltrating lymphocytes: Analysis by HLA restriction. Jlmmunother 10: 153–164 Ingram M, Jacques S, Freshwater DB, et al. (1987): Salvage immunotherapy of malignant glioma. Arch Surg 122: 1483–1486Google Scholar
  60. Itoh K, Platsoucas CD, Balch CM (1988): Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas: Activation by interleukin-2 and autologous tumor cells and involvement of the T cell receptor. J Exp Med 168: 1419–1441Google Scholar
  61. Itoh K, Tilden AB, Balch CM (1986): Interleukin-2 activation of cytotoxic T-lymphocyte infiltrating into human metastatic melanomas. Cancer Res 46: 30113017Google Scholar
  62. Itoh K, Tilden AB, Kumagai K, et al. (1985): Leu 11 positive lymphocytes with natural killer activity are precursors of recombinant interleukin-2 induced activated killer cells. J Immunol 134: 802Google Scholar
  63. Jacob SK, Wilson DJ, Kornblith PL, et al. (1986): Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res 46: 2101–2104Google Scholar
  64. Kasid A, Morecki S, Aebersold P, et al. (1990): Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviralmediated gene transfer in man. Proc Natl Acad Sci USA 87: 473–477Google Scholar
  65. Kawakami Y, Rosenberg SA, Lotze MT (1988): Interleukin-4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 168: 2183–2191Google Scholar
  66. Kawakami Y, Zakut R, Topalian SL, et al. (1992): Shared human melanoma antigens: Recognition by tumor infiltrating lymphocytes in HLA-A2. 1-transfected melanomas. J Immunol 148: 638–643Google Scholar
  67. Kradin RL, Kurnick JT, Lazarus DS, et al. (1989): Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1: 577–580Google Scholar
  68. Kragel AH, Travis WD, Steis RG, et al. (1990): Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66: 1513–1516Google Scholar
  69. Kriegler M (1990): Gene Transfer and Expression. A Laboratory Manual. New York: Stockton Press, pp. 1–242Google Scholar
  70. Kuppner MC, Hamou MF, de Tribolet N (1988): Immunohistological and functional analyses of lymphoid infiltrates in human glioblastomas. Cancer Res 48: 6926–6932Google Scholar
  71. Kurnick JT, Kradin RL, Blumberg R, et al. (1986): Functional characterization of T lymphocytes propagated from human lung carcinoma. Clin Immunol Immunopathol 38: 367–380Google Scholar
  72. Lafreniere R, Rosenberg SA (1985a): Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J Immunol 135: 4273–4280Google Scholar
  73. Lafreniere R, Rosenberg SA (1985b): Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukin-2. Cancer Res 45: 3735–3741Google Scholar
  74. Lafreniere R, Rosenberg SA (1986): A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst 76: 309–322Google Scholar
  75. Lee RE, Gaspari AA, Lotze MT, et al. (1988): Interleukin-2 and psoriasis. Arch Dermatol 124: 1811–1815 Lee RE, Lotze MT, Skibber JM, et al. (1989): Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 7: 7–20Google Scholar
  76. Lefor AT, Rosenberg SA (1991): The specificity of lymphokine activated killer (LAK) cells in vitro: Fresh normal murine tissues are resistant to LAK-mediated lysis. J Surg Res 50: 15–23Google Scholar
  77. Ley V, Roth C, Langlade-Demoyen P, et al. (1990): A novel approach to the induction of specific cytolytic T cells in vivo. Res Immunol 141: 855–863Google Scholar
  78. Lotze MT, Frana LW, Sharrow SO, et al. (1985a): In vivo administration of purified human interleukin-2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin-2. J Immunol 134: 157–166Google Scholar
  79. Lotze MT, Grimm EA, Mazumder A, et al. (1981): Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420–4425Google Scholar
  80. Lotze MT, Line BR, Mathisen DJ, et al. (1980): The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): Implications for the adoptive immunotherapy of tumors. J Immunol 125: 1487–1493Google Scholar
  81. Lotze MT, Matory YL, Ettinghausen SE, et al. (1985b): In vivo administration of purified human interleukin-2. II. Half-life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2. J Immunol 135: 2865–2875Google Scholar
  82. Lotze MT, Matory YL, Rayner AA, et al. (1986): Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer 58: 2764–2772Google Scholar
  83. Mazumder A, Rosenberg SA (1984): Successful immunotherapy of NK-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin-2. J Exp Med 159: 495–507Google Scholar
  84. Mazumder A, Eberlein TJ, Grimm EA, et al. (1984): Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer 53: 896–905Google Scholar
  85. Merchant RE, Merchant LH, Cook SHS, et al. (1988): Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor. Neurosurgery 23: 725–732Google Scholar
  86. Miller A, Buttimore C (1986): Redesign of retrovirus packaging cell lines to avoid recombinant leading to helper virus production. Mol Cell Biol 6: 2895–2902 Miller AD, Rosman GK (1989): Improved retroviral vectors for gene transfer and expression. Bio Techniques 7: 980–986Google Scholar
  87. Morgan DA, Ruscetti FW, Gallo RG (1976): Selective in vitro growth of T lymphocytes from normal bone marrow. Science 193: 1007–1008Google Scholar
  88. Mulé JJ, Ettinghausen SE, Spiess PJ, et al. (1986a): The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: An analysis of survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res 46: 676–683Google Scholar
  89. Mulé JJ, Shu S, Rosenberg SA (1985): The anti-tumor efficacy of lymphokine activated killer cells and recombinant interleukin-2 in vivo. J Immunol 135: 646–652Google Scholar
  90. Mulé JJ, Shu S, Schwarz SL, et al. (1984): Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487–1489Google Scholar
  91. Mulé JJ, Yang J, Shu S, et al. (1986b): The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo. Direct correlation between reduction of established metastases and cytolytic activity of lymphokine activated killer cells. J Immunol 136: 3899–3909Google Scholar
  92. Muul LM, Director EP, Hyatt CL, et al. (1986): Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy. J Immunol Methods 88: 265–275Google Scholar
  93. Muul LM, Narson-Burchenal K, Carter CS, et al. (1987a): Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. J Immunol Methods 101: 171–181Google Scholar
  94. Muul LM, Spiess PJ, Director EP, et al. (1987b): Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 138: 989–995Google Scholar
  95. Negrier S, Phillip T, Stoter G, et al. (1989): Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicentre study. Eur J Cancer Clin Oncol 25: S21 - S28Google Scholar
  96. Nitta T, Sato K, Yagita H, et al. (1990): Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368–371Google Scholar
  97. Ognibene FP, Rosenberg SA, Lotze M, et al. (1988): Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94: 750–754 Ortaldo JR, Mason A, Overton R (1986): Lymphokine-activated killer cells: Analysis of progenitors and effectors. J Exp Med 164: 1193Google Scholar
  98. Ottow RT, Eggermont AM, Steller EP, et al. (1987a): The requirements for successful immunotherapy of intra-peritoneal cancer using interleukin-2 and lymphokine-activated killer cells. Cancer 60: 1465–1473Google Scholar
  99. Ottow RT, Stellar EP, Sugarbaker PH, et al. (1987b): Immunotherapy of intraperitoneal cancer with interleukin-2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol 104: 366–376Google Scholar
  100. Paciucci PA, Holland JF, Glidewell O, et al. (1989): Recombinant interleukin-2 continuous infusion and adoptive transfer of recombinant interleukin-2 activated cells in patients with advanced cancer. J Clin Oncol 7: 869–878Google Scholar
  101. Paine JT, Handa H, Yamasaki T, et al. (1986): Immunohistochemical analysis of infiltrating lymphocytes in central nervous system tumors. Neurosurgery 18: 766772Google Scholar
  102. Papa MZ, Mule JJ, Rosenberg SA (1986): Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer Res 46: 49734978Google Scholar
  103. Phillips JH, Lanier LL (1986): Dissection of the lymphokine-activated killer phenomenon: Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164: 814Google Scholar
  104. Rabinowich H, Cohen R, Bruderman I, et al. (1987): Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 47: 173177Google Scholar
  105. Radrizzani M, Gambacorti-Passerini C, Parmiani G, et al. (1989): Lysis by interleukin-2 stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells. Cancer Immunol Immunother 28: 67–73Google Scholar
  106. Rayner AA, Grimm EA, Lotze MT, et al. (1985): Lymphokine-activated killer (LAK) cells: Analysis of factors relevant to the immunotherapy of human cancer. Cancer 55: 1327Google Scholar
  107. Rivoltini L, Avienti F, Orazi A, et al. (1992): Phenotypic and functional analysis of lymphocytes infiltrating pediatric tumors, with a characterization of the tumor phenotype. Cancer Immunol Immunother 34: 241–251Google Scholar
  108. Roberts K, Lotze MT, Rosenberg SA (1987): Separation and functional studies of the human lymphokine-activated killer cell. Cancer Res 47: 4366Google Scholar
  109. Rosenberg SA (1984): Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. J Biol Resp Mod 3: 501–511Google Scholar
  110. Rosenberg SA (1991): Adoptive cellular therapy: Clinical applications. In: Biologic Therapy of Cancer, DeVita VT, Hellman S, Rosenberg SA, eds. Philadelphia: J.B. Lippincott, Chapter 12, pp. 214–236Google Scholar
  111. Rosenberg SA (1992a): The immunotherapy and gene therapy of cancer. J Clin Oncol 10: 180–199 Rosenberg SA (1992b): Gene therapy of cancer. In. Important Advances in Oncology, Devita VT, Hellman S, Rosenberg SA, eds. Philadelphia: J.B. Lippincott pp. 17–38Google Scholar
  112. Rosenberg SA, Terry W (1977): Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25: 323–388Google Scholar
  113. Rosenberg SA, Aebersold P, Cornetta K. et al. (1990): Gene transfer into humans—Immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Eng! J Med 323: 570–578Google Scholar
  114. Rosenberg SA, Grimm EA, McGrofan M, et al. (1984): Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223: 1412–1415 Rosenberg SA, Longo DL, Lotze MT (1989a): Principles and applications of biologic theory. In: Cancer, Principles and Practices of Oncology, DeVita VT, Hellman, S, Rosenberg, SA, eds. Philadelphia: J.B. Lippincott, pp. 1342–1398Google Scholar
  115. Rosenberg SA, Lotze MT, Muul LM, et al. (1985a): Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Eng! J Med 313: 1485–1492Google Scholar
  116. Rosenberg SA, Lotze MT, Muul LM, et al. (1987): A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889–905Google Scholar
  117. Rosenberg SA, Lotze MT, Yang JC, et al. (1989b): Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485Google Scholar
  118. Rosenberg SA, Mule JJ, Spiess PJ, et al. (1985b): Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161: 1169–1188Google Scholar
  119. Rosenberg SA, Packard BS, Aebersold PM, et al. (1988a): Use of tumor-infiltrating lymphocytes and interleukin2 in the immunotherapy of patients with metastatic melanoma. N Eng! J Med 319: 1676–1680Google Scholar
  120. Rosenberg SA, Schwarz S, Spiess P (1988b): Combination immunotherapy of cancer: Synergistic anti-tumor interactions of interleukin-2, alpha-interferon and tumor infiltrating lymphocytes. J Natl Cancer Inst 80: 13931397Google Scholar
  121. Rosenberg SA, Spiess P, Lafreniere R (1986): A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes. Science 233: 13181321Google Scholar
  122. Rosenstein M, Ettinghausen SE, Rosenberg SA (1986): Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin-2. J Immunol 137: 1735–1742Google Scholar
  123. Rosenstein M, Yron I, Kaufman Y, et al. (1984): Lymphokine-activated killer cells: Lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2. Cancer Res 44: 1946–1953Google Scholar
  124. Rubin JT, Elwood LJ, Rosenberg SA, et al. (1989): Immunohistochemical correlates of response to recombinant interleukin-2 based immunotherapy in humans. Cancer Res 49: 7086–7092Google Scholar
  125. Saito T, Tanaka R, Yoshida S, et al. (1988): Immunohistochemical analysis of tumor-infiltrating lymphocytes and major histocompatibility antigens in human gliomas and metastatic brain tumors. Surg Neurol 29: 435–442Google Scholar
  126. Saris SC, Rosenberg SA, Friedman RB, et al. (1988): Penetration of recombinant interleukin-2 across the blood cerebrospinal fluid barrier. J Neurosurg 69: 29–34Google Scholar
  127. Schoof DD, Gramolini BA, Davidson DL, et al. (1988): Adoptive immunotherapy of human cancer using low-dose recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48: 5007–5010Google Scholar
  128. Schwartzentruber D, Lotze MT, Rosenberg SA (1988): Colonic perforation: An unusual complication of therapy with high-dose interleukin-2. Cancer 62: 23502353Google Scholar
  129. Schwartzentruber DJ, Topalian SL, Mancini MJ, et al. (1991a): Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-a, and IFN-y by human tumor-infiltrating lymphocytes after autologous tumor stimulation. Jlmmunol 146: 153–164Google Scholar
  130. Schwartzentruber DJ, White DE, Zweig MH, et al. (1991b): Thyroid dysfunction associated with immunotherapy for patients with cancer. Cancer 68: 2384–2390Google Scholar
  131. Shiloni E, Eisenthal A, Sachs D, et al. (1987): Antibody dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin-2. J Immunol 138: 1992–1998Google Scholar
  132. Shiloni E, Lefreniere R, Mulé JJ, et al. (1986): Effect of immunotherapy with allogeneic lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (RIL2) on established pulmonary and hepatic metastases in mice. Cancer 46: 5633–5640Google Scholar
  133. Shimizu K, Okamoto Y, Miyao Y, et al. (1987): Adoptive immunotherapy of human meningeal gliomatosis and carcinomatosis with LAK cells and recombinant interleukin-2. J Neurosurg 66: 519–521Google Scholar
  134. Skibber JM, Lotze MT, Uppenkamp I, et al. (1987): Identification and expansion of human lymphokine-activated killer cells: Implications for the immunotherapy of cancer. J Surg Res 42: 613Google Scholar
  135. Spiess PJ, Yang JC, Rosenberg SA (1987): In vitro antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 79: 1067–1075Google Scholar
  136. Stahel RA, Sculier J, Jost LM, et al. (1989): Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 (ala 125) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol 25: 965–972Google Scholar
  137. Steis R, Bookman M, Clark J, et al. (1987): Intraperitoneal lymphokine activated killer (LAK) cell and interleukin-2 (IL-2) therapy for peritoneal carcinomatosis toxicity, efficacy, and laboratory results (abstract). Proc Annu Meet Am Soc Clin Oncol 6: 250Google Scholar
  138. Stotter H, Weibke EA, Tornita S, et al. (1992): Cytokines after target cell susceptibility to lysis: II. Evaluation of tumor infiltrating lymphocytes. J Immunol 148: 638643Google Scholar
  139. Tagaki S, Chen K, Schwarz R, et al. (1989): Functional and phenotypic analysis of tumor-infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant interleukin-2. Cancer 63: 102–111Google Scholar
  140. Taniguchi T, Matsui H, Fujita T, et al. (1983): Structure and expression of a cloned cDNA for human interleukin-2. Nature 303: 305–307Google Scholar
  141. Teng MN, Park BH, Koeppen HKW, et al. (1991): Longterm inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 88: 3535–3539Google Scholar
  142. Tepper RL, Pattengale P, Leder P (1989): Murine interleukin-4 displays potent anti-tumor active in vivo. Cell 57: 503–512Google Scholar
  143. Thompson JA, Lee DJ, Lindgren CG, et al. (1989): Influence of schedule of interleukin-2 administration on therapy with interleukin-2 and lymphokine activated killer cells. Cancer Res 49: 235–240Google Scholar
  144. Topalian SL, Solomon D, Avis FP, et al. (1988): Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6: 839–853Google Scholar
  145. Topalian SL, Solomon D, Rosenberg SA (1989). Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714–3725Google Scholar
  146. Urba WJ, Clark JW, Steis RG, et al. (1989): Intraperitoneal lymphokine-activated killer cell/interleukin-2 therapy in patients with intraabdominal cancer: Immunologic considerations. J Natl Cancer Inst 81: 602–611Google Scholar
  147. Wang AM, Creasy AA, Ladner MB, et al. (1985): Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 228: 149–154Google Scholar
  148. Wang A, Lu S-D, Mark DF (1984): Site-specific mut-agenesis of the human interleukin-2 gene: Structure-function analysis of the cysteine residues. Science 224: 1431–1433Google Scholar
  149. Webb DE, Austin HA, Belldegrun A, et al. (1988): Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol 30: 141145Google Scholar
  150. Weber JS, Rosenberg SA (1990): Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor infiltrating lymphocytes. J Natl Cancer Inst 82: 755–761Google Scholar
  151. Weiss GR, Margolin KA, Aronson FR, et al. (1992): A randomized phase II trial of continuous infusion inter-leukin-2 or bolus injection interleukin-2 plus lymphokine activated killer cells for advanced renal cell carcinoma. J Clin Oncol 10: 275–281Google Scholar
  152. West WH, Tauer KW, Yannelli JR, et al. (1987): Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl Med 316: 898–905Google Scholar
  153. Whiteside TL, Miescher S, Hurlimman J, et al. (1986a): Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother 23: 169–178Google Scholar
  154. Whiteside TL, Miescher S, Hurlimann J, et al. (1986b): Separation, phenotyping, and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors. Int J Cancer 38: 803–811Google Scholar
  155. Yang JC, Mulé J, Rosenberg SA (1986): Murine lymphokine-activated killer (LAK) cells: Phenotypic characterization of the precursor and effector cells. J Immunol 137: 715–722Google Scholar
  156. Yang JC, Perry-Lalley D, Rosenberg SA (1990): An improved method for growing murine tumor infiltrating lymphocytes with in vivo antitumor activity. J Biol Response Md 9: 149–159Google Scholar
  157. Yasumoto K, Miyazaki K, Nagashima A, et al. (1987): Induction of lymphokine activated killer cells by intra-pleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 47: 2184–2187Google Scholar
  158. Yoshida S, Tanaka R, Takai N, et al. (1988): Local administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with malignant brain tumors. Cancer Res 48: 50115016Google Scholar
  159. Yron I, Wood TA, Spiess PJ, et al. (1980): In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol 125: 238–245Google Scholar

Copyright information

© Birkhäuser Boston 1993

Authors and Affiliations

  • Stephen E. Ettinghausen
  • Steven A. Rosenberg

There are no affiliations available

Personalised recommendations